NGMUnknown
NGM BIOPHARMACEUTICALS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for NGM BIOPHARMACEUTICALS INC (NGM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are NGM insiders buying or selling?
NGM BIOPHARMACEUTICALS INC insiders reported 203 open-market buys ($363.7M) and 24 sells ($12.8M) across 227 Form 4 filings — a net buying position of $350.9M.
Source: SEC EDGAR Form 4
Key Statistics (as of Nov 17, 2023)
Total Form 4 filings
227
SEC EDGAR
Insider filers
8
Insider buys (203)
$363.7M
Insider sells (24)
$12.8M
Insider sentiment
Net buyingNet insider flow of $350.9M in net buying.
Recent NGM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 22.6K | $0.69 | $15.5K |
| Nov 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 22.6K | $0.69 | $15.5K |
| Nov 17, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 22.6K | $0.69 | $15.5K |
| Nov 17, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 26.8K | $0.68 | $18.3K |
| Feb 1, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K |
| Feb 1, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K |
| Feb 1, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K |
| Feb 1, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K |
| Jan 23, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K |
| Jan 23, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K |
| Jan 23, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K |
| Jan 23, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K |
| Jan 18, 2023 | Jin-Long Chen | Chief Scientific Officer | Sale | 85.1K | $5.15 | $438.3K |
| Jan 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K |
| Jan 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K |
| Jan 17, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K |
| Jan 17, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K |
| Jan 12, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M |
| Jan 12, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M |
| Jan 12, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M |
| Jan 12, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M |
| Dec 14, 2022 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K |
| Dec 14, 2022 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K |
| Dec 14, 2022 | Peter Svennilson | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K |
| Dec 14, 2022 | David V Goeddel | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K |
Showing the 25 most recent of 227 Form 4 filings for NGM BIOPHARMACEUTICALS INC.
Most active NGM insiders
- Peter Svennilson115 filings
- David V Goeddel54 filings
- Peter Svennilson32 filings
- Jin-Long Chen20 filings
- Hsiao D Lieu3 filings
Ask anything about NGM insider activity
Use Trabud's AI agent to query NGM BIOPHARMACEUTICALS INC's Form 4 history in plain English — "Show me NGM CEO purchases this year" or compare it against any other ticker.
Open the AI agentNGM insider trading FAQ
Are NGM BIOPHARMACEUTICALS INC insiders buying or selling?
Across 227 SEC Form 4 filings, NGM BIOPHARMACEUTICALS INC (NGM) insiders reported 203 open-market purchases totaling $363.7M and 24 sales totaling $12.8M. That is a net buying position of $350.9M.
How many insiders trade NGM stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for NGM BIOPHARMACEUTICALS INC. The most recent filing was accepted on Nov 17, 2023.
Where does Trabud get NGM insider trading data?
All NGM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.